{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:37:38Z","timestamp":1700325458768},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2002,4,1]]},"DOI":"10.1038\/sj.bmt.1703522","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:18:47Z","timestamp":1031249927000},"page":"577-580","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT"],"prefix":"10.1038","volume":"29","author":[{"given":"I","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wentling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JL","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"PL","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AR","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,4,30]]},"reference":[{"key":"BF1703522_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","volume":"310","author":"B Barlogie","year":"1984","unstructured":"Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents New Engl J Med 1984 310: 1353 1356","journal-title":"New Engl J Med"},{"key":"BF1703522_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","volume":"2","author":"D Samson","year":"1989","unstructured":"Samson D, Gaminara E, Newland A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma Lancet 1989 2: 882 885","journal-title":"Lancet"},{"key":"BF1703522_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0277-5379(84)90188-3","volume":"20","author":"H Kantarjian","year":"1984","unstructured":"Kantarjian H, Dreicer R, Barlogie B et al. High dose cytosine arabinoside in multiple myeloma Eur J Clin Oncol 1984 20: 227 231","journal-title":"Eur J Clin Oncol"},{"key":"BF1703522_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/BF00689456","volume":"35","author":"RK Ganjoo","year":"1995","unstructured":"Ganjoo RK, Williams A, Malpas J . Vincristine and oral etoposide in refractory multiple myeloma Cancer Chemother Pharmacol 1995 35: 343 344","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703522_CR5","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1200\/JCO.1989.7.10.1514","volume":"7","author":"B Barlogie","year":"1989","unstructured":"Barlogie B, Velasquez WS, Alexanian R et al. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma J Clin Oncol 1989 7: 1514 1517","journal-title":"J Clin Oncol"},{"key":"BF1703522_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2","volume":"52","author":"MA Dimopoulos","year":"1996","unstructured":"Dimopoulos MA, Weber D, Kantarjian H et al. Hyper CVAD for VAD-resistant multiple myeloma Am J Hematol 1996 52: 77 81","journal-title":"Am J Hematol"},{"key":"BF1703522_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma New Engl J Med 1999 341: 1565 1571","journal-title":"New Engl J Med"},{"key":"BF1703522_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","volume":"109","author":"G Juliusson","year":"2000","unstructured":"Juliusson G, Celsing F, Malm C et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma Br J Haematol 2000 109: 89 96","journal-title":"Br J Haematol"},{"key":"BF1703522_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4065\/75.9.897","volume":"75","author":"S Rajkumar","year":"2000","unstructured":"Rajkumar S, Fonseca R, Dispenzieri A et al. Thalidomide in the treatment of relapsed multiple myeloma Mayo Clin Proc 2000 75: 897 901","journal-title":"Mayo Clin Proc"},{"key":"BF1703522_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2141.2000.01835.x","volume":"108","author":"A Kneller","year":"2000","unstructured":"Kneller A, Raanani P, Ben-Bassat I et al. Therapy with thalidomide in refractory multiple myeloma patients \u2013 the revival of an old drug Br J Haematol 2000 108: 391 393","journal-title":"Br J Haematol"},{"key":"BF1703522_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BGM Durie","year":"1975","unstructured":"Durie BGM, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival Cancer 1975 36: 842 854","journal-title":"Cancer"},{"key":"BF1703522_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/8371","volume":"5","author":"BF Hales","year":"1999","unstructured":"Hales BF . Thalidomide on the comeback trail Nat Med 1999 5: 489 490","journal-title":"Nat Med"},{"key":"BF1703522_CR13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PAJ, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1 J Immunol 1999 163: 380 386","journal-title":"J Immunol"},{"key":"BF1703522_CR14","first-page":"409","volume":"86","author":"P Tosi","year":"2001","unstructured":"Tosi P, Ronconi S, Zamagni E et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation Haematologica 2001 86: 409 413","journal-title":"Haematologica"},{"key":"BF1703522_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/sj.bmt.1702444","volume":"25","author":"A Zomas","year":"2000","unstructured":"Zomas A, Anagnostopoulos N, Dimopoulos MA . Successful treatment of multiple myeloma relapsing after high dose therapy and autologous transplantation with thalidomide as a single agent Bone Marrow Transplant 2000 25: 1319 1320","journal-title":"Bone Marrow Transplant"},{"key":"BF1703522_CR16","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"96","author":"T Hideshima","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 2000 96: 2943 2950","journal-title":"Blood"},{"key":"BF1703522_CR17","first-page":"604a","volume":"94","author":"DM Weber","year":"1999","unstructured":"Weber DM, Gavino M, Delasalle K et al. Thalidomide alone or with dexamethasone for multiple myeloma Blood 1999 94: 604a","journal-title":"Blood"},{"key":"BF1703522_CR18","doi-asserted-by":"crossref","first-page":"273b","DOI":"10.1182\/blood.V92.1.273.413a32_273_282","volume":"92","author":"B Barlogie","year":"1998","unstructured":"Barlogie B, Desikan R, Munshi N et al. Single course DTPACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma Blood 1998 92: 273b","journal-title":"Blood"},{"key":"BF1703522_CR19","first-page":"123a","volume":"94","author":"N Munshi","year":"1999","unstructured":"Munshi N, Desikan R, Zangari M et al. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma Blood 1999 94: 123a","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703522","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T01:51:21Z","timestamp":1682041881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,4,1]]}},"alternative-id":["BF1703522"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703522","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4,1]]},"assertion":[{"value":"20 November 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}